- PR Newswire•4 days agoConsiderable Additional Benefit of Eisai's Halaven® (eribulin) in Advanced Liposarcoma Confirmed by the German Federal Joint Committee (G-BA)
HATFIELD, England, December 4, 2016 /PRNewswire/ -- FOR EMEA MEDIA ONLY: NOT FOR SWISS/AUSTRIAN JOURNALISTS Eribulin has shown unprecedented survival benefit in advanced liposarcoma in pivotal ...
- PR Newswire•8 days agoHalaven® (eribulin) Receives Registration in South Africa for Treatment of Women With Advanced Breast Cancer
Halaven® (eribulin) is now registered by the Medicines Control Council (MCC) in South Africa for the treatment of women with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease. Eribulin was discovered and developed by Eisai and will be available to people in South Africa through a partnership with Equity Pharma, part of Clinigen's Link Healthcare division. Approximately 7,000 women are diagnosed with breast cancer in South Africa each year. Eribulin monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease.
- Motley Fool•last month
Milestone payments from partner Eisai help Arena perform better in Q3 than expected.
ESALY : Summary for EISAI CO SPON ADR REP 1 COM NPV - Yahoo Finance
Eisai Co., Ltd. (ESALY)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||54.88 - 56.25|
|52 Week Range||53.55 - 66.38|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||25.35|
|Dividend & Yield||1.26 (2.18%)|
|1y Target Est||N/A|